Mutant KRAS at the Heart of Tumor Immune Evasion
- PMID: 31951548
- DOI: 10.1016/j.immuni.2019.12.013
Mutant KRAS at the Heart of Tumor Immune Evasion
Abstract
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. Nature. 2019. PMID: 31666701 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
